Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD



Status:Recruiting
Healthy:No
Age Range:22 - Any
Updated:2/20/2019
Start Date:February 18, 2018
End Date:December 2020

Use our guide to learn which trials are right for you!

A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support

This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow
extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive
mechanical ventilation for patients who require respiratory support due to an acute
exacerbation of Chronic Obstructive Pulmonary Disease (COPD). It is hypothesized that the
Hemolung RAS can be safely used to avoid or reduce time on invasive mechanical ventilation
compared to COPD patients treated with standard-of-care mechanical ventilation alone.
Eligible patients will be randomized to receive lung support with either the Hemolung RAS
plus standard-of-care mechanical ventilation, or standard-of-care mechanical ventilation
alone.

The Hemolung RAS provides low-flow ECCO2R using a single, 15.5 French dual-lumen catheter
inserted percutaneously in the femoral or jugular vein. Low-flow ECCO2R offers an alternative
or supplement to invasive mechanical ventilation (MV) for patients suffering from acute,
reversible, hypercapnic respiratory failure. In contrast to invasive MV, low-flow ECCO2R
provides partial ventilatory support independently of the lungs. The rationale for this study
is that low-flow ECCO2R with the Hemolung RAS can be used to provide supplemental CO2 removal
in COPD patients experiencing acute hypercapnic respiratory failure to either avoid or reduce
time on invasive MV. In this patient population, avoidance or reduced time on invasive MV may
have significant clinical benefit in reducing the many complications associated with invasive
MV. The major complication risks of low-flow ECCO2R are associated with central venous
catheterization and the need for anticoagulation during treatment. This study is designed to
evaluate the safety and efficacy of Hemolung RAS plus standard-of-care as compared to
standard-of-care alone.

Inclusion Criteria:

1. Age ≥ 22 years

2. Confirmed diagnosis of underlying COPD (based on prior spirometry or approved
screening procedure) or ACOS (Asthma-COPD Overlap Syndrome) based on prior spirometry
or approved screening procedure.

3. Diagnosed as experiencing an acute exacerbation of COPD

4. Subject has been receiving standard of care treatment for an acute exacerbation of
COPD, including treatment with bronchodilators, corticosteroids, antibiotics, and
controlled oxygen therapy.

5. Able to generate adequate cough and control of secretions

6. Minimum platelet count of 100,000/mm3 (and not requiring daily transfusions to
maintain platelet count above 100,000/mm3) at time of screening.

7. Minimum hemoglobin of 7.0 gm %, no active major bleeding (and not requiring daily
transfusions to maintain hemoglobin count above 7.0 gm%) at time of screening.

8. Informed consent from patient or legally authorized representative

9. Meets one of the 2 following sets of population stratification criteria:

1. (Stratum 1) Has required noninvasive ventilation (NIV) for ≤ 4 days, and

1. Is at high risk of requiring intubation and invasive mechanical ventilation (MV) after
at least one hour on NIV due to one or more of the following:

-Respiratory acidosis (arterial pH < 7.25) despite NIV

-Worsening hypercapnia or respiratory acidosis relative to baseline blood gases

-No improvement in PaCO2 relative to baseline blood gases and presence of moderate or
severe dyspnea

-Presence of tachypnea > 30 breaths per minute

- Intolerance of NIV with failure to improve or worsening acidosis, dyspnea or work
of breathing

*OR*

2. After starting NIV with a baseline arterial pH ≤ 7.25, shows signs of progressive
clinical decompensation manifested by decreased mental capacity, inability to tolerate
NIV, or increased or decreased respiratory rate in setting of worsened or unchanged
acidosis.

2. (Stratum 2) Meets ALL of the following criteria:

-Has required intubation and invasive MV due to acute respiratory failure for ≤ 4
days, either immediately upon presentation or after having failed NIV

-PaCO2 ≥ 50 mmHg prior to intubation

- Has met criteria for weaning readiness

- Has failed first spontaneous breathing trial due to increased dyspnea, rate of
breathing, work of breathing, and/or dynamic hyperinflation (i.e. reasons
associated with hypercapnia)

- Able to protect airway

Exclusion Criteria:

1. DNR/DNI order

2. Presence of acute, uncontrolled arrhythmia

3. Hemodynamic instability (mean arterial pressure < 60 mmHg) despite infusion of
vasoactive drugs

4. Acute coronary syndrome

5. Acute exacerbation is due primarily to congestive heart failure

6. PaO2/FiO2 < 120 mmHg on PEEP >/= 5 cmH2O

7. Current intubation (Stratum 2), or likelihood of intubation (Stratum 1), or will
occur, greater than 24 hours but less than 72 hours after prior extubation

8. Presence of bleeding diathesis or other contraindication to anticoagulation
therapy

9. Significant weakness or paralysis of respiratory muscles due to causes unrelated
to acute exacerbation of COPD

10. Cerebrovascular accident, intracranial bleed, head injury or other neurological
disorder likely to adversely affect ventilation or airway protection.

11. Hypersensitivity to heparin or history of previous heparin-induced
thrombocytopenia (HIT Type II)

12. Presence of a significant pneumothorax or bronchopleural fistula

13. Current uncontrolled, major psychiatric disorder

14. Current participation in any other interventional clinical study

15. Pregnant women (women of child bearing potential require a pregnancy test)

16. Neutropenic (absolute neutrophil count < 1,00mm3, not transient) related to the
presence or treatment of a malignancy; recent bone marrow transplant (within
prior 8 months); current, uncontrolled AIDS; or receiving long-term (>3 months)
high dose immunosuppressants within the last 6 months.

17. Presence of severe (acute or chronic) renal failure defined as requiring any form
of dialysis.

18. Severe liver insufficiency (Child-Pugh scores >7) or INR > 1.6 suspected to be
related to liver disease (liver associated coagulopathy)

19. Diagnosis of acute pulmonary embolism during current ICU admission

20. Known vascular abnormality or unavailable vascular access which could complicate
or prevent successful Hemolung Catheter insertion

21. Terminal patients not expected to survive current hospitalization

22. Ventilated via tracheotomy

23. Presence or history of clinically significant disease or other foreseeable risk
that outweighs the potential, in the judgement of the investigator
We found this trial at
31
sites
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Matthew Exline, MD
Phone: 614-307-6011
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Nick Hill, MD
Phone: 617-636-4288
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Raghu Seethala, MD
Phone: 609-721-1937
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Abhijit Duggal, MD
Phone: 216-445-3960
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Principal Investigator: Kevin Doerschug, MD
Phone: 319-384-6482
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Christian Bermudez, MD
Phone: 215-614-0329
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Mitchell Levy, MD
Phone: 401-444-4961
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Boris Medarov, DO
Phone: 518-262-5196
?
mi
from
Albany, NY
Click here to add this to my saved trials
Allentown, Pennsylvania 18105
Principal Investigator: Jennifer Rovella, MD
Phone: 610-402-9543
?
mi
from
Allentown, PA
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Principal Investigator: James Blum, MD
Phone: 404-712-8463
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Charlottesville, Virginia 22908
Principal Investigator: Kyle Enfield, MD
Phone: 434-962-2318
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: Jigme Sethi, MD
Phone: 412-327-5264
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Robert Balk, MD
Phone: 312-942-6744
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Jessica Mullins, MD
Phone: 214-645-6493
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Neil MacIntyre, MD
Phone: 919-681-2720
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Falls Church, Virginia 22042
Principal Investigator: Christopher King, MD
Phone: 703-269-4759
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
Gainesville, Florida 32610
Principal Investigator: Tiago-Noguchi Machuca, MD
Phone: 352-273-5501
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Lance Cohen, MD
Phone: 561-370-9426
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Bindu M Akkanti, MD
Phone: 281-908-7912
?
mi
from
Houston, TX
Click here to add this to my saved trials
500 S Preston St
Louisville, Kentucky
(502) 852-5555
Principal Investigator: Mohamed Saad, MD
Phone: 502-852-1359
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Asif Saberi, MD
Phone: 770-422-1372
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Minneapolis, Minnesota 55407
Principal Investigator: Ramiro Saavedra-Romero, MD
Phone: 612-863-6288
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
Principal Investigator: Sabiha Hussain, MD
Phone: 732-235-5965
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Hyde Park, New York 11040
Principal Investigator: Seth Koenig, MD
Phone: 917-403-2284
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Daniel Brodie, MD
Phone: 212-305-1554
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Michael Benninghoff, MD
Phone: 302-623-7600
?
mi
from
Newark, DE
Click here to add this to my saved trials
Peoria, Illinois 61637
Principal Investigator: William P Tillis, MD
Phone: 309-308-9694
?
mi
from
Peoria, IL
Click here to add this to my saved trials
1801 N Broad St
Philadelphia, Pennsylvania 19122
(215) 204-7000
Principal Investigator: Gerard J Criner, MD
Phone: 215-510-6570
Temple University Temple University is many things to many people. A place to pursue life's...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Brian Morrissey, MD
Phone: 916-734-3565
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Zafar Jamkhana, MD
Phone: 314-577-8460
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Shreveport, Louisiana 71103
Principal Investigator: L K Scott, MD
Phone: 318-675-6094
?
mi
from
Shreveport, LA
Click here to add this to my saved trials